David Brill

David Brill serves as senior vice president of portfolio management at Paragon Biosciences. He focuses on investment prospect generation, structuring, execution, and due diligence. In addition, he provides strategic corporate advice and oversight to Paragon portfolio companies.

David Brill, M.D., has more than 15 years of experience in the healthcare industry including investment management, equity research, venture capital, and operations. Prior to Paragon, he was an operating partner at Abundant Venture Partners and led the spinout of ignite Health from Edwards Lifesciences. Dr. Brill previously served as a senior healthcare analyst for Citadel Global Equities and Point72 Asset Management where he was responsible for all investment activities in the medical technology sector. He began his career in the medical device industry with Medtronic in various corporate development roles and moved into finance as a senior equity research associate covering medical technology for Wells Fargo Securities. Dr. Brill completed medical school at Georgetown University School of Medicine and earned an MBA from the University of Pennsylvania’s Wharton School. He also holds a bachelor’s degree in biological sciences from Northwestern University.